Announced Thu, 23 Jul · 13:30 IST
Solara Q1 FY27: Highest EBITDA and PAT in 18 quarters; Revenue up 20% YoY
Compliance View source PDF
SOLARA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-8.1%1-day move
₹537.80
prior close
₹526.00
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.6+1.5+1.0+7.1-8.1-6.6————————
Up moveDown movePending
AI summary
Solara reported Q1 FY27 revenues of INR 3,843 Mn, up 20% YoY, with EBITDA at INR 635 Mn (up 10% YoY) and PAT at INR 163 Mn (up 55% YoY), the highest in 18 quarters. Base business drove growth with revenues of INR 3,077 Mn (up 24% YoY) and EBITDA of INR 722 Mn (up 8% YoY), despite West Asia input cost pressures. Ibuprofen business shows EBITDA loss of INR 87 Mn. Net debt reduced by INR 1,346 Mn to INR 4,795 Mn.
Likely market impact
Strong quarter as base business drives growth and debt falls; Ibuprofen drag and geopolitical input costs remain watchpoints.